Stryker: A Dividend Growth Stock Value Idea

NEW YORK ( F.A.S.T. Graphs) -- As the stock market continues to advance, it's getting harder and harder to find exciting investments at fair values. However, regardless of whether the overall market is high or low, there are always bargains to be had.

There is a lot of uncertainty surrounding health care today. Therefore, I believe it is one sector where bargains can be found. Consequently, I offer Stryker ( SYK) as an example of an above-average dividend growth stock that is currently attractively valued.

Stryker is a leader in developing orthopedic implants, MedSurg equipment, neurotechnology and spine products. Approximately 45% of its revenue come from orthopedic implants, MedSurg equipment at 38%, and neurotechnology and spine products 17%.

Stryker has been actively launching new products to strengthen its already extensive portfolio that includes artificial hips, knees and other orthopedic implants. Recent press releases include: On March 15 Stryker announced the launch of the ES2 Spinal System, on March 13 it introduced the ICONIX All Suture Anchor Platform, and on March 11 Stryker announced the launching of the Universal SMARTLock Hybrid MMF System.



Additionally, Stryker recently acquired Trauson Holdings Company Limited, a leading trauma manufacturer in China and a major competitor in the spine segment. Stryker believes that with this acquisition it is well-positioned to expand in China and other emerging markets regions.

Consequently, worldwide demographics and Stryker's leading innovations in medical development and manufacturing position the company for continued growth.

Stryker -- Fundamentally Attractive

This article is intended to look at Stryker's "essential fundamentals at a glance" through the lens of the F.A.S.T. Graphs earnings and price correlated research tool. Before analyzing a company for investment, it's important to have a perspective on how well the business has performed. Because, at the end of the day, if you are an investor you are buying the business. The orange line on the graph plots earnings per share since 1999. A quick glance vividly reveals the excellent and consistent historical operating record of Stryker.

If you liked this article you might like

These Stocks Are Ready to Reverse Course

Don't Get Out of Joint

Zimmer Biomet: Cramer's Top Takeaways

Market Stands at a Make-Or-Break Level: Cramer's 'Mad Money' Recap (Monday 7/17/17)

Analyst Says Rival Bidder Could Emerge for Novadaq After Stryker Deal